SALT LAKE CITY, March 07, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that it will participate in Roth’s 35th Annual Healthcare Conference set for March 12th-14th and in Renmark Financial Communications Inc.’s Virtual Non-Deal Roadshow Series on March 7th and 22nd.
EVENT DETAILS:
Roth 35th Annual Healthcare Conference, March 12-14
Presentation/Fireside Chat Time: March 13 starting at 3:30 p.m. E.D.T
Webcast link: https://wsw.com/webcast/roth46/clnn/1826765
The webcast of this presentation will be posted to the Investors section of the Company’s website located at www.invest.clene.com.
Renmark Virtual Non-Deal Roadshow Series
Rob Etherington, Chief Executive Officer, and Morgan Brown, Chief Financial Officer, will deliver the latest investor presentation followed by a live Q&A session. Individuals can register by using the link below.
March 7 – 4 p.m. EDT, https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-clnn-2023-03-07-130000
March 22 – 2 p.m. EDT, https://www.renmarkfinancial.com/events/renmark-virtual-non-deal-roadshow-nasdaq-clnn-2023-03-22-130000
Registration for the Renmark events may be limited but access to the replays will be posted to the Investors section of the Company’s website within a few days of the events. To ensure smooth connectivity, please access this link using the latest version of Google Chrome.
About Clene
Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease by targeting energetic failure, an underlying cause of many neurological diseases. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on Twitter, LinkedIn and Facebook.
Contacts:
Renmark Financial Communications Inc.
James R. Kautz: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel.: (416) 644-2020 or (212) 812-7680
www.renmarkfinancial.com
| Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. (858) 717-2310 | Investor Contact Kevin Gardner LifeSci Advisors This email address is being protected from spambots. You need JavaScript enabled to view it. 617-283-2856 |
| Last Trade: | US$5.30 |
| Daily Change: | -0.59 -10.02 |
| Daily Volume: | 133,956 |
| Market Cap: | US$42.290M |
December 10, 2024 November 13, 2024 October 09, 2024 October 01, 2024 September 30, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
